Tesamorelin Amino Acid Sequence Length Explained
A reference breakdown of the tesamorelin amino acid sequence length, how it compares to native GHRH, and why residue count shows up on listings and COAs.
Reviewed by Yuki Tanaka, PhD, molecular biologist ·
Yuki Tanaka, PhD is a molecular biologist with a doctorate from Osaka University and postdoctoral training at Stanford School of Medicine, specializing in growth hormone axis biology, GHRH receptor signaling, and synthetic peptide analog mechanisms.
The tesamorelin amino acid sequence length is 44 residues. That figure comes directly from its design as a modified analog of human growth hormone-releasing hormone (GHRH), which is itself a 44-amino-acid peptide in its most commonly referenced form. Tesamorelin keeps that same backbone length while adding a small chemical modification at one end of the chain, which is why suppliers and COAs describe it as a GHRH(1-44) analog rather than a shortened or truncated fragment.
Why the Sequence Length Matters on a Listing
Sequence length is one of the identity markers that distinguishes a specific peptide from related compounds in the same family. When a listing states “44 amino acids,” it is telling a reader that the backbone matches full-length GHRH rather than a fragment variant. Some GHRH-related research compounds on the market are deliberately shortened, such as sequences built around the first 29 residues of GHRH. Those are structurally distinct products, not interchangeable with a 44-residue tesamorelin sequence, even though they belong to the same broader peptide family.
This distinction matters for anyone comparing listings across suppliers. A product page, spec sheet, or certificate of analysis (COA) that references molecular weight, sequence length, or the GHRH(1-44) designation is describing structural identity, not a claim about what the compound does once handled.
The N-Terminal Modification
What separates tesamorelin from unmodified GHRH is not the count of amino acids but a chemical addition at the N-terminus of the chain: a trans-3-hexenoic acid group attached to the first residue. This modification does not add or remove any amino acid from the 44-residue sequence. It sits on top of the existing chain. That is why documentation sometimes describes tesamorelin as “GHRH(1-44) with an N-terminal modification” rather than listing a different residue count than native GHRH.
Because the modification adds mass without changing the amino acid count, molecular weight figures on a COA will differ from unmodified GHRH(1-44) even though both share the same 44-residue backbone. A reader comparing two documents should check whether they are looking at sequence length, molecular weight, or both, since they answer different questions.
How Sequence Length Appears in Documentation
A COA or supplier spec sheet typically lists several identity fields together. The table below shows how sequence length fits alongside the other figures a reader is likely to see.
| Field | What it describes | Typical tesamorelin value |
|---|---|---|
| Sequence length | Number of amino acid residues in the chain | 44 |
| Parent sequence | Reference peptide the analog is based on | GHRH (1-44) |
| N-terminal modification | Chemical group added to residue 1 | Trans-3-hexenoic acid |
| Molecular formula | Full atomic composition | Listed per-lot on COA |
| Molecular weight | Mass of the modified peptide | Higher than unmodified GHRH(1-44) due to the added group |
Not every listing includes all of these fields. A minimal product page may state only the sequence length and molecular weight, while a full COA from mass spectrometry or HPLC testing will typically include the molecular formula and a measured mass that a reader can check against the expected value for the modified sequence.
Comparing Sequence Length to Purity Testing
Sequence length describes what the peptide is designed to be; it does not describe how closely a given vial matches that design. A COA showing a purity percentage from HPLC testing is a separate measurement from the sequence length itself, and confirming the correct number of residues typically relies on mass spectrometry, which reports a measured mass rather than a residue count directly. If a supplier states a molecular weight for a 44-residue tesamorelin sequence, a reader can compare that stated figure against the mass spec result on the COA to check for internal consistency.
For anyone comparing sourcing documentation across multiple suppliers, checking whether the stated sequence length, parent GHRH reference, and molecular weight are all consistent with each other is a straightforward first check before looking at purity data at all. Some reference catalogs, including heezresearch.com/research/tesamorelin/, lay out these identity fields alongside lot-specific COA data so the two types of information are not mixed together on the same line.
Sequence Length Versus Fragment Naming Conventions
Peptide naming conventions in this space often reference the residue range directly, such as “GHRH(1-44)” or “GHRH(1-29).” Reading these designations correctly means understanding that the numbers describe which residues of the parent sequence are present, not a dosage or strength figure. A 44-residue designation on a tesamorelin listing is describing the full parent chain, modified at one terminus; it says nothing about vial size, reconstitution volume, or concentration, which are separate figures found elsewhere on a spec sheet.
Readers who are cross-referencing multiple listings for the tesamorelin amino acid sequence length sometimes find inconsistent formatting between suppliers. Some write “44 aa,” others write “GHRH(1-44) analog,” and others simply state the molecular formula and expect the reader to infer the residue count. None of these formats change the underlying figure; they are different conventions for presenting the same identity data. For side-by-side listing comparisons across sources, peer tesamorelin listing catalogs aggregate spec fields from multiple product pages in a consistent layout and track how vial size and pricing relate to the same identity specs discussed here.
Summary
Tesamorelin’s amino acid sequence length is 44 residues, matching the full-length GHRH backbone it is derived from, with a trans-3-hexenoic acid modification added at the N-terminus rather than any change to the residue count. This figure functions as an identity marker on listings and COAs, distinct from purity percentage, molecular weight, or vial concentration, and understanding how it fits alongside those other fields makes supplier documentation easier to read and compare.
A note on how to read this
This article is written for research and educational reference. The materials described are sold for laboratory research and are not for human consumption. Nothing here is dosing guidance, a prescription, or a clinical recommendation.